Enrol for latest cancer treatments
Welcome to the groundbreaking Immunotherapy Enrolment of latest treatment facilitated by OPSAN. We invite you to check your eligibility for new immunotherapy approved by FDA (Food and Drug Administration, USA). This is limited only to a few patients and will be served on first come first serve basis.
Which treatments are offered?
Breast cancer
Trastuzumab Deruxtecan (T-DXd)
Pertuzumab
Taxane
Transtuzumab
AZD9833 (an Oral SERD) plus Palbociclib
Anastrozole plus Palbociclib
ARV-471 VS FULVESTRANT
Trastuzumab
Advanced Solid Tumors
HPK1 Inhibitor
Anti-PD-1 Monoclonal Antibody Pembrolizumab
Anti PD-L1 Atezolizumab
Melanoma
Adjuvant MK-7684A (Vibostolimab with Pembrolizumab)
Pembrolizumab
Lung cancer
CA-170 in Combination with Chemotherapy
HPK1 Inhibitor
Anti-PD-1 Monoclonal Antibody Pembrolizumab
Anti PD-L1 Atezolizumab
Urinary bladder cancer
TAR-200
Cetrelimab
Intravesical Bacillus Calmette-Guérin (BCG)
TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy
Ewing sarcoma
Albociclib
Irinotecan
Temozolomide
Cyclophosphamide
Hodgkin's Lymphoma
HPK1 Inhibitor
Anti-PD-1 Monoclonal Antibody Pembrolizumab
Anti PD-L1 Atezolizumab
Multiple Myeloma
Elranatamab
Lenalidomide
Gastroesophageal Cancer
Zanidatamab
Tislelizumab
Why to Join?
Pioneering Treatment
It focuses on harnessing the power of the immune system to target and eliminate cancer cells. This innovative approach holds immense promise in improving treatment outcomes.
Personalized Care
Expert team of oncologists and researchers will provide personalized care throughout the course, tailoring the treatment to your specific needs. Your health and well-being are our top priorities.
Comprehensive Monitoring
Throughout the course, you will receive thorough monitoring and follow-up care to ensure your safety and well-being. Expert team will closely track your progress and provide any necessary support.